Edgar Filing: Adamas Pharmaceuticals Inc - Form 4

Form 4	armaceuticals I	nc										
February 18, 2015 FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION												
-	UNITE	ED STATES	ITIES AND EXCHANGE CO hington, D.C. 20549				COMMISSION	OMB Number:	3235-0287			
Check th if no lon subject t Section Form 4 o Form 5 obligatio may con See Instr	ger o 16. or Filed tinue.	pursuant to 17(a) of the	OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES D Section 16(a) of the Securities Exchange Act of 1934, e Public Utility Holding Company Act of 1935 or Section h) of the Investment Company Act of 1940						Expires: January 31, 2005 Estimated average burden hours per response 0.5			
See Instruction 30(n) of the Investment Company Act of 1940 1(b).												
(Print or Type	Responses)											
BOOTH RICHARD H Symbol				ssuer Name and Ticker or Trading pol				5. Relationship of Reporting Person(s) to Issuer				
				s Pharmac 5]	euticals	Inc		(Check all applicable)				
				te of Earliest Transaction th/Day/Year) 7/2015				X Director 10% Owner Officer (give title Other (specify below) below)				
				nendment, Date Original onth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
EMERYVI	LLE, CA 9460)8							Iore than One Re			
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative	Secur	ities Acq	uired, Disposed of	, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction I (Month/Day/Ye	ear) Executio any	med on Date, if Day/Year)	3. Transactic Code (Instr. 8) Code V	(Instr. 3,	ispose	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Common Stock	02/17/2015			S	1,000	D	\$ 16.54	49,778 <u>(1)</u>	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: Adamas Pharmaceuticals Inc - Form 4

Reporting Owners

Reporting Owner Name / Address		Relationships						
	1	Director	10% Owner	Officer	Other			
BOOTH RICHARD H C/O ADAMAS PHARMACEUTICALS 1900 POWELL ST., SUITE 750 EMERYVILLE, CA 94608	, INC.	Х						
Signatures								
/s/Grace Shin, as Attorney-in-Fact	02/18/201	.5						

Date

**Signature of Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.